Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma

Glioblastoma (GBM) is the most common primary brain tumor with no available cure. As previously described, seliciclib, a first-generation cyclin-dependent kinase (CDK) inhibitor, down-regulates the anti-apoptotic protein, Mcl-1, in GBM, thereby sensitizing GBM cells to the apoptosis-inducing effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Noonan, Janis J., Jarzabek, Monika, Lincoln, Frank A., Cavanagh, Brenton L., Pariag, Arhona R., Juric, Viktorija, Young, Leonie S., Ligon, Keith L., Jahns, Hanne, Zheleva, Daniella, Prehn, Jochen H. M., Rehm, Markus, Byrne, Annette T., Murphy, Brona M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966586/
https://www.ncbi.nlm.nih.gov/pubmed/31842413
http://dx.doi.org/10.3390/cancers11122005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966586/
https://www.ncbi.nlm.nih.gov/pubmed/31842413
http://dx.doi.org/10.3390/cancers11122005

Ejemplares similares